Based on the current controversy regarding the prognostic significance of KIT mutations in CBF-AML, we primarily focused on CBF-AML as one group and sought to determine whether the clinical outcomes are associated with KIT mutations. The gene discussed is KIT; the disease is acute myeloid leukemia.